Background {#Sec1}
==========

The term xerosis is used to describe dryness in the epidermal layers of the skin. It is a common condition, which can result in scaling, flaking and itching \[[@CR1]\]. Risk factors for xerosis include sunlight, friction, low humidity, and use of soaps \[[@CR2]\]. Xerosis also presents as a symptom of cutaneous conditions such as psoriasis, dermatitis and ichthyosis \[[@CR3]\] with accompanying signs of inflammation and pain. The plantar area of the foot is particularly susceptible, due to its reliance on sweat secretions to remain hydrated \[[@CR4]\].

It is important to adequately manage xerosis so that epidermal barrier function is maintained, serving to protect underlying tissues and structures from infection and physical damage \[[@CR5]\]. Topical moisturisers are of benefit in managing xerosis \[[@CR6]\], with many studies showing a demonstrable improvement in skin condition when comparing use of a moisturiser with a 'sham' base cream \[[@CR7], [@CR8]\].

Moisturising products achieve their hydrating and/or moisture barrier properties from active ingredients included in the formulation. These ingredients are broadly classed as occlusives, humectants, emollients or rejuvenators \[[@CR5]\]. Categorised examples of some common active ingredients are shown in Table [1](#Tab1){ref-type="table"}.Table 1Examples of common active ingredients in respective categoriesHumectantsOcclusivesEmollientsRejuvenatorsGlycerinLanolinPetrolatumCollagenUreaParaffinVegetable oilKeratinAmmonium lactatePetrolatumDimethiconeElastinGelatinCholesterolPropylene glycolHyaluronic acidStearyl alcoholCastor oil

Occlusives form a hydrophobic barrier over the skin, preventing trans-epidermal water loss. Their limitations include a 'greasy' feel, odour and possible inclusion of potential allergens \[[@CR9]\]. Humectants enhance water transfer upward from the dermis to the epidermis and inwards from the external environment \[[@CR9]\]. Emollients improve skin texture by filling gaps and fissures \[[@CR9]\]. Rejuvenators are reported to act to replenish depleted essential skin proteins. These aid appearance by filling in fine lines \[[@CR5]\].

An effective moisturiser will ideally include at least both an occlusive and humectant to achieve beneficial hydrating properties \[[@CR10]\]. Although many products on the market include diverse combinations of these active ingredients \[[@CR11]\], it appears no specific ingredient, formulation or product has been identified in the literature as optimal or superior for the treatment of plantar foot xerosis. One systematic review \[[@CR12]\] that investigated treatments for dry skin found that moisturisers in general are effective, but no particular recommendations could be made due to lack of evidence. American guidelines on the treatment of atopic dermatitis state there are a lack of trials comparing moisturising agents in xerosis treatment (a prominent symptom of dermatitis), and the few that do exist do not display significant differences in efficacy \[[@CR13]\].

The objective of this systematic review was to identify, collate and critically appraise relevant literature investigating efficacy of treatments for primary foot xerosis in a general and diabetic population. The aim was to identify any particular ingredient or formulation that gave superior results in treating primary xerosis symptoms in the current literature. The following specific review question was formulated as the focus of the review: What is the most effective ingredient or formulation of topical treatments for symptoms of primary foot xerosis in the general population?

Methods {#Sec2}
=======

A flowchart of the search strategy is included in Fig. [1](#Fig1){ref-type="fig"}. A systematic search was undertaken to identify literature relevant to the review question. A synthesis of the literature was then conducted to identify active ingredients tested and the treatment results. The goal was to identify any ingredient that had been evaluated across multiple studies for treating xerosis.Fig. 1Preferred Reporting Items for Systematic Reviews and Meta -- Analyses (PRISMA) diagram

It was decided to include literature from all experimental study designs, as no well conducted randomised controlled trials were identified. Particular outcome measures could not be specified as a pre-requisite for inclusion, as the literature concerning the rating of xerosis severity varied markedly. There was an array of subjective and objective measurements described in the literature, and it was decided to include studies regardless of their specified outcome measures and allow them to be appraised using a rigorous critical appraisal tool. A narrative synthesis of included studies was then conducted to answer the clinical question.

It should be noted that while studies discussing xerosis as secondary to other diseases (such as eczema, psoriasis and ichthyosis) were excluded, studies focused on diabetic participants were allowed as the presentation and treatment of diabetic xerosis closely approximates that of xerosis in the non-diabetic population \[[@CR6]\]. In both instances, the treatment goal is to increase and retain moisture and therefore, structural integrity \[[@CR6]\]. Treatments for xerosis secondary to psoriasis or eczema often include corticosteroids and anti-inflammatory agents that counteract immunological responses in the skin, which are of little benefit to people outside of these populations \[[@CR14]\].

Full exclusion and inclusion criteria for studies are included in Table [2](#Tab2){ref-type="table"}.Table 2Inclusion and exclusion criteria for article search resultInclusionExclusionExperimental, quantitative study design\
Xerosis in foot/ft assessed by any method\
Studies after and including 1970\
Primary xerosis or xerosis secondary to Diabetes mellitus only\
Published in English\
Human participants\
Full text articlesXerosis in area other than foot/ft\
Xerosis secondary to disease (e.g. psoriasis, eczema)

Registration {#Sec3}
------------

The systematic review was registered with the PROSPERO International prospective register of systematic reviews on 15/02/2015, registration no. CRD42015017032.

Databases {#Sec4}
---------

A PICO question (population, intervention, comparator, outcome) (Table [3](#Tab3){ref-type="table"}) was devised to inform keywords, which were then used to search the following databases between September 20 and October 1 2014: EMBASE, AMED, Cochrane, MEDLINE, CINAHL, Ageline and SCOPUS. Search terms used were "xerosis" OR "dry skin" OR "ichthyosis" AND "feet" OR "foot" AND "moisturi\*" OR "emollient" OR "humectant" OR "occlusive" OR "skin cream". The following limits were applied when allowed: English language, years between 1970 -- present, experimental trials, humans. A complete search strategy for Medline is shown in Fig. [2](#Fig2){ref-type="fig"}.Table 3PICO format clinical questionPopulationGeneral population and diabetics with foot xerosisInterventionTopical moisturisersComparatorOther moisturisers, placebo, no treatmentOutcomeClinical scoring, instrumental measures Fig. 2Medline search strategy

Intervention studies from Levels II through to IV of the National Health and Medical Research Council (NHMRC) Hierarchy of Evidence \[[@CR15]\] were included. After duplicate references were removed, a title and abstract search was conducted by the principal investigator (JP). Articles that did not meet the eligibility criteria were then excluded. Included articles then underwent a 'pearling' process in which their reference lists were checked for articles missed in the initial search. All included articles were reviewed in full text by two independent assessors (JP and RS) against the Epidemiological Appraisal Instrument (EAI), a validated critical appraisal tool.

Data extraction {#Sec5}
---------------

Data were extracted to give an overview of the content of the included studies. Categories included were evidence level (as dictated by NHMRC) \[[@CR15]\], population studied, interventions tested, sample size, study duration, outcome measures utilised, inclusion criteria and study results.

Results {#Sec6}
=======

Thirty three articles qualified for full text review. Twelve were excluded for not meeting the eligibility criteria. Pearling through reference lists revealed 1 extra article, resulting in a total of 22 studies.

Appraisal tool {#Sec7}
--------------

Due to the varied nature of experimental designs in studies included in this review, it was necessary to find a critical appraisal tool that could be utilised across multiple experimental study designs. The Epidemiological Appraisal Instrument (EAI) developed by Genaidy et al. \[[@CR16]\] was chosen as the validated and reliable methodological appraisal tool to determine risk of bias in these studies. Appraisal of methodological bias was performed using the EAI by two independent reviewers (JP and RS). Any discrepancies were discussed and resolved at a face-to-face meeting.

Appraisal results {#Sec8}
-----------------

The results of the methodological appraisal have been condensed in Fig. [3](#Fig3){ref-type="fig"}. Of 22 studies, 15 scored in the 'average' category and 7 scored as 'poor'.Fig. 3Epidemiological Appraisal Instrument (EAI) scores of study methodological quality

Populations {#Sec9}
-----------

Nine \[[@CR7], [@CR8], [@CR17]--[@CR23]\] out of the 22 included studies featured samples with diabetes, with 2 of those solely focusing on Type 2 diabetes \[[@CR17], [@CR22]\]. Three studies were female--only \[[@CR4], [@CR19], [@CR24]\] with one including only menopausal women \[[@CR19]\]. Six studies had populations aged 40 years and over \[[@CR1], [@CR17], [@CR21], [@CR25]--[@CR27]\]. The youngest reported age in any study was 13 \[[@CR28]\] while the oldest was 97 years \[[@CR25]\].

Study designs {#Sec10}
-------------

The included studies fell into levels III −2. III −3 or IV in the NHMRC hierarchy of evidence \[[@CR15]\] for intervention studies, consisting of mainly comparative studies against other active interventions or controls, or pre-post-tests. Whilst several studies claimed to be randomised controlled trials, the descriptions indicated that these studies had no true controls or unsatisfactory randomisation of groups, and therefore could not be classified as level II evidence as defined in the NHMRC hierarchy. A large number of study designs featured participants testing different treatments on opposite feet, or having treatment applied to one foot while the other served as an untreated comparator. The least rigorous designs included were of a pre-post study design with no concurrent comparison groups (four studies).

Study durations ranged from 14 days to 7 months, with 28 days the most common duration (11 studies). Sample sizes ranged from 10 to 75 participants. Only one study \[[@CR17]\] included a prospective sample size calculation to obtain estimates of cohort numbers required to detect clinically important differences between groups.

Outcome measures {#Sec11}
----------------

A range of outcome measurements were utilised throughout the literature. Primary outcome measures were either objective clinical scoring methods to rate xerosis symptom severity, or instrumental measurements to evaluate physiological characteristics, such as moisture loss. Outcomes measured clinically as indicators of skin dryness included flakiness, callosity, cracking, fissuring, scales, flexibility and tenderness. These were evaluated visually and by palpation, individually assigned a score and then summed together as part of a 'composite' scoring system. Examples of composite scoring systems were the XAS (xerosis assessment score) and Overall Dryness Severity Score \[[@CR7], [@CR8], [@CR29]\]. A number of studies appeared to implement ad-hoc composite scoring methods, devised by individual study investigators to suit the needs of their experiment \[[@CR18], [@CR24], [@CR28], [@CR30]\].

Outcomes measured instrumentally as indicators of skin dryness included moisture retention, evaporation time, epidermal conductance, epidermal thickness, transcutaneous O~2~ and CO~2~ and skin pH.

No articles included in this review contained data pertaining to the validity or reliability (either inter or intra-rater) of the clinical or instrumental outcome measures utilised.

Interventions {#Sec12}
-------------

Table [4](#Tab4){ref-type="table"} lists the interventions used in each study. Most studies had interventions with different formulations of the tested products. All studies had some description of the most 'active' ingredients, and this review focused on these as being the most likely to contribute to any beneficial effect of the moisturiser. 'Minor' ingredient elements in each study have not been listed as it was beyond the scope of this study to investigate the individual physiological effects of these.Table 4Characteristics of included studies (listed in chronological order)StudyNHMRC LevelPopulationSample Size (n male)Intervention/active ingredients testedStudy durationOutcome measurementsInclusion CriteriaStudy resultsMean values/Effect sizeNash \[[@CR30]\]IVM/F, 12 -- 87 years75 (NR)20% urea cream7 monthsClinical scoringUTDSignificant improvement after treatmentN/AHopp and Sundberg \[[@CR27]\]III-1M/F, 60 + yrs60 (NR)Alpha-Keri (oil) vs Keri-lotion ® (both containing lanolin, mineral oil and emulsifiers) vs water soak vs control12 daysQuestionnaire,\
Dryness Scale,\
Panel evaluationUTDWater soak + Keri-lotion was superior to other combinationsMean difference\
1.16 (*P* \< 0.05)Brenner \[[@CR25]\]IVM/F, 53 -- 97 years10 (7)12% ammonium lactate14 days7-point Dry Skin Grading ScaleUTDSignificant improvement after treatmentN/ASiskin et al. \[[@CR29]\]III-2Sex NR, 24 -- 85 years55 (NR)12% ammonium lactate vs no therapy8 weeksOverall Dryness Severity Score,\
Physician Global Improvement of Improvement/Worsening≥ Moderate bilateral dryness12% ammonium lactate superior to no treatmentMean difference 0.98 (*P* \< 0.05)Jennings et al. \[[@CR33]\]III-3M/F, 22 -- 86 years70 (34)5% salicylic acid + 10% urea vs 12% ammonium lactate28 daysXerosis severity scale,\
Tenderness Scale,\
VASMild-moderate bilateral xerosisNo significant difference between treatmentsMean difference 0.1 (*P* = 0.15)Uy et al. \[[@CR28]\]III - 2Sex NR, 13 -- 72 years57 (NR)12% ammonium lactate vs liposome -- based emollients (petrolatum, paraffin)28 daysClinical grading scores≥ Moderate bilateral dryness and/or hyperkeratosisNo significant difference between treatmentsN/AAdemola et al. \[[@CR2]\]III-2M/F, 18 -- 65 years25 (NR)40% urea cream vs 12% ammonium lactate28 daysEvapirometer (roughness),\
Corneometer (dryness),\
D-Squame (scales),\
VAS≥ Grade 2 xerosis\
Free of cutaneous disease40% urea cream superiorEffect size 0.19 (95% CI: −0.47 to 0.84)Jennings et al. \[[@CR36]\]III-3M/F, 26 -- 83 years35 (10)10% lactic acid vs 12% ammonium lactate28 daysXerosis severity scale,\
Tenderness Scale,\
VASMild-moderate bilateral xerosisNo significant difference between treatments, patients preference for 10% lactic acidMean difference 0.1 (*P* = 0.9)Pham et al. \[[@CR7]\]III-2M/F, age NR40 (22)10% urea + 4% lactic acid vs placebo vehicle28 daysXerosis Assessment Scale≥18 years\
Type 1 or 2 diabetes\
Mild-moderate bilateral xerosis10% urea + 4% lactic acid superior to placebo vehicleN/ABaird \[[@CR20]\]III-3M/F, age NR30 (14)10% urea cream vs 25% urea cream6 weeksCustomised equipment measuring skin electrical resistanceType 1 or 2 diabetes\
Bilateral dry skin25% urea cream superior to 10% urea creamEffect size 0.27 (95% CI: −0.24 to 0.78)Jennings et al. \[[@CR37]\]III-3M/F, 18 + yrs41 (NR)Lanolin cream vs 12% ammonium lactate28 daysXerosis severity scale,\
Tenderness Scale,\
VASModerate-severe bilateral xerosisNo significant difference between treatmentsN/ABaker and Rayman \[[@CR21]\]III-3M/F, 40 -- 74 years26 (12)10% urea foam vs 'patient's regular creams' (aqueous cream, Diprotobase and Unguentum)14 days5-point scale for dryness, flexibility and callus formationType 1 or 2 diabetes\
Neuropathic\
Bilateral xerosis10% urea foam superior to patient's existing creamsEffect size −2.33) (95% CI: −2.99 to −1.59)Quatrezoos\
et al. \[[@CR19]\]III-2Female, 55 -- 62 years30 (0)Chitlin -- Glucan vs placebo vehicle + glycerol35 daysMoisture Accumulation Test (MAT)Menopausal women\
Type 1 or 2 diabetes\
Mod -- severe xerosisChitlin-Glucan superior to placebo vehicle, equal result to glycerol yet longer-lastingMean difference of 60 pointsDe Soca and De Atencio \[[@CR18]\]IVM/F, 20 -- 50 year40 (NR)10% urea cream28 daysClinical scoring,\
VAS,\
Hydrometer,\
Skin pH20 -- 50 yo\
'Normal' body weight\
Type 1 or 2 diabetesSignificant improvement after treatmentMean difference of 5.4Baalham et al. \[[@CR4]\]III-3Female, age NR15 (0)Paraffin vs Paraffin + 10% urea14 daysDigital moisture monitorAdult\
Free of cutaneous disease\
Bilateral xerosisParaffin + 10% urea superiorEffect size 0.87 (95% CI: 0.1 to 1.59)Garrigue et al. \[[@CR8]\]III-2M/F, 18 -- 75 years54 (24)Pedimed ® (urea, lactic acid, paraffin) vs placebo vehicle28 daysXerosis Assessment Score (XAS),\
D-Squame\
CorneometerM / F\
18 -- 25\
Type 1 or 2 diabetes\
Mod -- severe xerosisPedimed ® superior to placebo vehicle18% difference between groups (*P* \< 0.05)Grossman et al. \[[@CR1]\]IVM/F, 41 -- 70 year12 (6)35% urea foam28 daysClinical grading score,\
Global assessment score≥18 years\
Xerosis diagnosis as per Global Assessment ScoreSignificant improvement after treatmentN/APapanas et al. \[[@CR22]\]III-2M/F, age NR20 (10)10% urea foam vs no treatment14 daysCorneometerType 2 diabetes10% urea foam was superior to no treatmentEffect size 1.25 (95% CI: 0.55 to 1.9)Ciammaichella et al. \[[@CR23]\]III-2M/F, age NR54 (29)5% urea cream vs no treatment28 daysMicroangiopathy,\
Ultrasound,\
Partial O~2~ + CO~2~ pressures,\
VAS scaleDiabetes - Insulin treated\
Stable control\
Defined neuropathy5% urea cream superior to no treatmentN/ADykes \[[@CR24]\]III-3Female, 22 -- 64 years25 (0)25% urea cream vs unspecified urea cream14 daysClinical photo scores,\
Corneometer18+ years old\
Visibly dry feet\
Otherwise healthy25% urea cream more effective than unspecified urea creamEffect size −0.26 (95% CI: −0.83 to 0.35)Federici, Federici and Milani \[[@CR17]\]III-2M/F, 40 -- 75 years40 (16)Urea, arginine and carnosine cream vs glycerol cream28 daysDryness Area Severity Index (DASI score),\
VAS score40 -- 75 years\
Mod -- severe xerosis\
Type 2 diabetesUrea, arginine and carnosine cream superiorMean difference −0.8Loden, von Scheele and Michelsen \[[@CR3]\]III-3M/F, 21 -- 86 years50 (25)15% alphahydroxy acid + 15% urea cream vs healthy controls14 daysTrans-epidermal water loss (TEWL),\
Clinical scores,\
VASUTD15% alphahydroxy acid + 15% urea significantly improved skin condition in both symptomatic and healthy samplesN/A*III-2* comparative study with concurrent controls, *III-3* comparative study without concurrent controls, *IV* case series with either post-test or pre-test/post-test outcomes (as per \[[@CR15]\]); *NR* not reported, *n* sample size, *yrs* years, *UTD* unable to determine, *n* sample size; *M* male; *F* female, *VAS* visual analogue scale; *CI* confidence interval

Twelve major active ingredients were identified in the literature. Urea was the most frequently listed primary active or co-active ingredient - it was tested in interventions across 14 of the included studies. This should not be construed as implying that urea is the most effective product, however, merely the most researched.

Alphahydroxy acid, arginine, carnosine and salicylic acid all appeared individually once in the literature. It should be noted that all were combined with urea, and hence it is likely that any beneficial effects observed cannot be solely attributed to them. Arginine and carnosine in particular were both combined with urea in comparison studies against a glycerol formulation. It is unclear what effect these ingredients may have when used individually.

Follow up periods {#Sec13}
-----------------

Two studies \[[@CR2], [@CR28]\] featured a follow--up period, in which the longevity of beneficial effects was assessed after treatment stopped. Both studies found no statistical difference.

Discussion {#Sec14}
==========

The aim of this systematic review was to identify the most effective ingredient or formulation of moisturiser to treat dry skin of the foot. The heterogeneous nature of populations, methodologies and outcome measures made meta-analysis of the literature impossible as a method of answering the review question.

Populations varied in the included literature, particularly in terms of age and diabetic status. One study \[[@CR19]\] focussed on menopausal diabetic women, although it was not clarified how this group differed to other populations. Both increasing age and diabetes exacerbate the occurrence and severity of xerosis \[[@CR26]\]. Including these alongside healthy younger populations in the review was deemed acceptable as the underlying pathophysiology and course of treatment for primary xerosis is similar regardless of age or diabetic status \[[@CR6]\].

Out of the 22 studies included, only one \[[@CR17]\] included a prospective sample size calculation. Without such a calculation, a study may have insufficient statistical power to be able to detect a clinically worthwhile difference between groups \[[@CR31]\]. Accordingly, the results from the studies included in this review, even though some are statistically significant, may not reflect clinically worthwhile effects.

Outcome measures were particularly variable, including instrumental measurements, clinical scoring systems, 'expert opinion' and photographs. None of the studies reported validity or reliability testing of outcome measures or reporting of previous scores. This was curious for studies involving instrumental measures, as there is available literature validating several of these measures for epidermal hydration \[[@CR32]\].

Numerous studies \[[@CR3], [@CR7], [@CR17], [@CR33]\] claimed to use a randomised trial design, but upon review were found to be randomising allocation of moisturisers to the left and right feet of participants, rather than randomising participants into distinct groups as dictated by NHMRC criteria \[[@CR15]\]. As such, there were no true level II randomised controlled trials included in this review.

The overall quality of articles was 'poor' to 'average' when tested against a validated critical appraisal tool \[[@CR16]\] with none appraised as 'good'. Recruitment, randomisation and blinding techniques (if used) were often not explained in sufficient detail. Not all studies explained the criteria by which a diagnosis of 'xerosis' was made and how it was differentiated, for example, from a fungal infection or systemic disease.

Most studies in this review relied on the participant applying cream to their own feet. While self-application seems the most practical method for daily intervention application (especially when a study extends for weeks or months), there is no guarantee the participant will be compliant to the extent dictated by their respective trial, which may impact on efficacy data. Efforts were often made to control for this, by asking participants to fill out diaries and by weighing the contents of moisturiser bottles pre and post-trial. Application of cream by a blinded third party would appear the ideal method in these experimental study designs. The patient acceptance of the product will also have an impact on the compliance of the patient, should the product be greasy or difficult to apply, this may influence the patient applying the moisturiser regularly \[[@CR34]\], and should be the subject of further studies.

Studies only mentioned major active ingredients. However, many treatments in these studies included an array of 'minor' ingredients. These included additives such as emulsifiers, alcohols and fats \[[@CR35]\]. These additional ingredients may play a part in determining product efficacy and subsequently affect the outcomes of the studies.

As well as ingredient effectiveness, the question of ideal individual ingredient concentrations may also be raised. Two studies compared urea creams of different concentrations \[[@CR20], [@CR24]\], both showing that higher concentration urea creams had a superior effect. A 40% urea cream was shown to have a dramatically increased keratolytic effect on skin when compared to 10% urea cream \[[@CR14]\]. Evaluating ideal ingredient concentrations to treat specific skin conditions would require the attention of more focussed studies.

It is not only desirable to identify the most effective moisturising ingredients, but also those with the longest--lasting effects after treatment cessation. Considering the ongoing nature of skin dryness and the challenge of patient compliance in treatment, it may be of clinical interest for a future paper to examine which ingredients or formulations produce the longest--lasting skin hydrating effects between applications.

Limitations of this review include the selection of articles by one author only and only full text and English language papers being included. A further limitation, due to the poor quality of the literature available with disparate outcome measures and minimal reporting of results, is that analysis methods such as effect size calculation could only be conducted on a small amount of the literature. Meta-analysis was unable to be conducted, thus limiting what could be construed with regard to most effective moisturiser from the review.

Conclusion {#Sec15}
==========

A synthesis of available literature reveals that treatments containing urea as a primary active ingredient are the most prolifically researched for treating symptoms of xerosis in the foot. However, this observation is based on literature of a poor to average methodological quality. Larger-scale randomised trials comparing competing treatments would help ascertain optimum formulations and concentrations of ingredients for the treatment of foot xerosis. Furthermore, these trials should endeavour toward higher quality study designs in which they: (i) use validated and reliable outcome measures, (ii) conduct and report prospective power calculations for required sample numbers, (iii) treat individual participants as one sample, and (iv) have the intervention applied in a controlled environment to facilitate compliance.

Not applicable.

Funding {#FPar1}
=======

Nil.

Availability of data and materials {#FPar2}
==================================

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Authors\' contributions {#FPar3}
=======================

JP, RS and SJ conceived the review. JP ran the database search. RS and JP reviewed the articles. JP drafted the manuscript and all authors reviewed and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

Not applicable.
